TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells

IntroductionAmplification of the TNK2 gene in primary tumours correlates with poor prognosis. In accordance, TNK2 overexpression was shown to promote invasion of cancer cells – but the mechanism by which TNK2 mediates these effects is unresolved. TNK2 was suggested to regulate Cdc42-driven migration by activation of breast cancer antioestrogen resistance 1 (BCAR1); however, distinct from this effect is evidence for a role of TNK2 in the regulation of epidermal growth factor receptor (EGFR) endocytosis and degradation. In the present study we sought to investigate whether negative targeting of TNK2 by siRNA could be used to inhibit cancer cell invasion, to establish the contribution of its effect on the EGFR and to consequently attempt to resolve the issue of TNK2's mechanism of action.MethodsWe used siRNA to knockdown expression of TNK2 and its proposed effector BCAR1 in order to analyse the effect of this knockdown on cancer cell behaviour in vitro. We examined morphological changes using phase-contrast microscopy and immunohistochemistry. Functional parameters examined included apoptosis, proliferation, migration and invasion. We also performed flow cytometry analysis to examine EGFR cell surface expression and carried out western blot to examine the total EGFR levels.ResultsWe observed that targeting of TNK2 by siRNA in breast cancer cells resulted in distinct morphological changes characterised by a stellate appearance and an absence of protrusions at membrane edges. These changes were not recapitulated upon siRNA targeting of BCAR1. We thus hypothesised that a component of the effects induced by TNK2 may be independent of BCAR1. Consistent with the idea of an alternative mechanism for TNK2, we observed that TNK2 associates with activated EGFR in breast cancer cells in a TNK2-kinase-independent manner. Furthermore, we demonstrated that TNK2 functions to maintain EGFRs on the cell surface. We could demonstrate that the main functional effect of activating these surface EGFRs in breast cancer cells is stimulation of migration. In accordance, TNK2 silencing by siRNA led to a significant reduction in cell surface EGFR and to a concomitant decrease in the migratory and invasive capacity of breast cancer cells.ConclusionOur data suggest that TNK2 can enhance migration and invasion of breast cancer cells via preservation of EGFR expression, notwithstanding its previously reported signalling via BCAR1, explaining its oncogenic behaviour in vitro and correlation with metastatic human breast cancer in vivo.

[1]  P. Keely,et al.  Ack1 Mediates Cdc42-dependent Cell Migration and Signaling to p130Cas* , 2006, Journal of Biological Chemistry.

[2]  Alfredo Ribeiro Silva.  Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. , 2006, International journal of surgical pathology.

[3]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[4]  E. Gelmann,et al.  Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. , 1987, Molecular endocrinology.

[5]  Alan Hall,et al.  Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.

[6]  H. Maruta,et al.  The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation , 1999, Oncogene.

[7]  L. Lim,et al.  A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42 , 1993, Nature.

[8]  J. Baselga,et al.  PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  H. Maruta,et al.  Construction of a Cell‐Permeable CDC42 Binding Fragment of ACK That Inhibits v‐Ha‐Ras Transformation , 1999, Annals of the New York Academy of Sciences.

[10]  F. J. Blok,et al.  Epidermal growth factor receptors associated to cytoskeletal elements of epidermoid carcinoma (A431) cells , 1986, The Journal of cell biology.

[11]  R. Cerione,et al.  Cloning and Characterization of a Novel Cdc42-associated Tyrosine Kinase, ACK-2, from Bovine Brain* , 1997, The Journal of Biological Chemistry.

[12]  R. Cerione,et al.  The Cdc42 Target ACK2 Interacts with Sorting Nexin 9 (SH3PX1) to Regulate Epidermal Growth Factor Receptor Degradation* , 2002, The Journal of Biological Chemistry.

[13]  J. Boonstra,et al.  The EGF receptor is an actin-binding protein , 1992, The Journal of cell biology.

[14]  K. V. van Golen,et al.  Rho-Regulatory Proteins in Breast Cancer Cell Motility and Invasion , 2004, Breast Cancer Research and Treatment.

[15]  S. Powers,et al.  Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Yi Shen,et al.  Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. , 2006, Cancer research.

[17]  Y. Kaziro,et al.  Activation of the guanine nucleotide exchange factor Dbl following ACK1-dependent tyrosine phosphorylation. , 2000, Biochemical and biophysical research communications.

[18]  R. Cerione,et al.  Activated Cdc42 Sequesters c-Cbl and Prevents EGF Receptor Degradation , 2003, Cell.

[19]  Xiaoxiao Gao,et al.  New agents in development for breast cancer , 2007, Current opinion in obstetrics & gynecology.

[20]  James L Mohler,et al.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.

[21]  Wannian Yang,et al.  Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. , 2007, Molecular biology of the cell.

[22]  P. Bertics,et al.  Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity. , 1995, Endocrinology.

[23]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[24]  M. Symons,et al.  The Transcription Factor AP-1 Is Required for EGF-induced Activation of Rho-like GTPases, Cytoskeletal Rearrangements, Motility, and In Vitro Invasion of A431 Cells , 1998, The Journal of cell biology.

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Schlessinger,et al.  Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Epstein,et al.  Growth factor induced activation of Rho and Rac GTPases and actin cytoskeletal reorganization in human lens epithelial cells. , 2003, Molecular vision.

[28]  M. Teo,et al.  The Tyrosine Kinase ACK1 Associates with Clathrin-coated Vesicles through a Binding Motif Shared by Arrestin and Other Adaptors* , 2001, The Journal of Biological Chemistry.

[29]  L. Van Aelst,et al.  Rho GTPases: signaling, migration, and invasion. , 2000, Experimental cell research.

[30]  Ho-Yyoung Lee,et al.  Resistance to epidermal growth factor receptor-targeted therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.